ZYMEWORKS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ZYMEWORKS INC. (ZYME) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $14.15 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-02
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $14.15M, a 531.22% increase from fiscal 2024.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $2.24M, a 195.78% increase from fiscal 2023.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $758.00K, a 1330.19% increase from fiscal 2022.
- ZYMEWORKS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $53.00K, a 99.52% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $14.15M 10-K · filed 2026-03-02 |
| 2024-12-31 | $2.24M 10-K · filed 2026-03-02 |
| 2023-12-31 | $758.00K 10-K · filed 2026-03-02 |
| 2022-12-31 | $53.00K 10-K · filed 2025-03-05 |
| 2021-12-31 | $11.00M 10-K · filed 2024-03-06 |
| 2020-12-31 | $19.45M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |